Bone marrow-derived mesenchymal stem cells for treatment of heart diseases

Recent clinical trials suggest that bone marrow–derived cell preparations can ameliorate left ventricular (LV) remodeling in patients with acute and chronic ischemic cardiomyopathy (ICM). The aim of these trials is to compare the safety and efficacy of transplantation of allogenic versus autologous bone-derived mesenchymic stem cells (MSCs) for treating dilated cardiomyopathy and chronic ischemic left ventricular dysfunction (LVD) secondary to myocardial infarction. In treatment of LVD, allogeneic and autologous MSCs did not stimulate immunologic reactions and had little adverse effects, while favorably affecting patient functional capacity, quality of life, and ventricular remodeling.